Doug Chaet of Value Evolutions Sees Value-based Care Programs as Just That: an Evolution
October 18th 2022Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends.
Read More
Will Keytruda and Opdivo Finally Get Some Price Competition? | AMCP Nexus 2022
October 14th 2022EQRx has said it will price its PD-1/PDL-1 inhibitor 40% below the price of the entrenched PD-1/PDL-1 inhibitors, says Bhavesh Shah of Boston Medical Center Health System. But there are obstacles looming, including the development of combination therapies.
Read More
Trikafta Effective But Costly, Says Prime Therapeutics | AMCP Nexus 2022
October 14th 2022A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.
Read More
Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022
October 13th 2022Express Scripts' Aimee Tharaldson discussed the growing number of gene therapies in her keynote talk today on specialty drug at AMCP Nexus 2022. She listed 12 approved gene therapies, eight in the near-term pipeline for hemophilia and another seven for other diseases that may be approved next year.
Read More
Accumulators, Maximizers Exacerbate Healthcare Disparities, Says Janssen Research | AMCP Nexus 2022
October 13th 2022Research by Janssen shows that non-White patients are disproportionately affected by the accumulators and maximizers that PBMs use to blunt the financial consequences of copay assistance cards.
Read More
What You Need To Know About Medicare Part B Step Therapy: AMCP Nexus 2022
October 12th 2022Yuqian Liu, Pharm.D., and Michelle Booth, Pharm.D., of Magellan Rx Management, discuss the background and consequences of step therapy in Medicare Part B in an interview prior to their session at the AMCP Nexus 2022 meeting in National Harbor, Maryland.
Read More
The former Baltimore city health commissioner has been criticized for some of her views on COVID-19 mandates. In her talk opening the AMCP Nexus 2022 meeting, Wen said that if public health officials don’t take into account public attitudes, it could affect the ability to deal with future public health emergencies.
Read More
Some Humira Biosimilar Customers Are Taking a Wait-and-See Approach
October 6th 2022Tom Newcomer, head of U.S. market access for Samsung Bioepis, maker of Hadlima, a Humira biosimilar, said some potential customers want to see which biosimilars will grab a large market share before deciding on which one to buy
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Read More
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
Thyroid Abnormalities Rare Among Children with Vitiligo, Study Finds
September 26th 2022The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.
Read More